background
may
contribut
pathophysiolog
airway
inflamm
exampl
recent
shown
nasal
administr
produc
late
phase
coappear
granulocyt
plasma
exud
marker
mucos
surfac
object
present
studi
examin
indic
granulocyt
presenc
activ
respons
intranas
challeng
healthi
subject
patient
allerg
rhiniti
examin
season
subject
nasal
challeng
shamcontrol
crossov
design
nasal
lavag
carri
prior
hour
post
challeng
nasal
biopsi
obtain
post
challeng
nasal
lavag
fluid
level
myeloperoxidas
mpo
eosinophil
cation
protein
ecp
analyz
indic
neutrophil
eosinophil
activ
moreov
macroglobulin
analyz
marker
proinflammatori
cytokin
product
plasma
exud
nasal
biopsi
number
neutrophil
eosinophil
monitor
result
nasal
lavag
fluid
level
mpo
record
hour
post
challeng
increas
healthi
subject
p
patient
allerg
rhiniti
p
cf
sham
challeng
similarli
macroglobulin
increas
healthi
subject
p
patient
allerg
rhiniti
p
lavag
fluid
level
ecp
affect
challeng
increas
number
subepitheli
neutrophil
p
number
eosinophil
conclus
produc
nasal
inflammatori
respons
human
characteris
late
phase
ie
hour
post
challeng
neutrophil
activ
plasma
exud
tumour
necrosi
import
proinflammatori
cytokin
immun
system
dysregul
respons
implic
sever
inflammatori
diseas
includ
rheumatoid
arthriti
condit
antagon
either
recombin
solubl
receptor
neutralis
antibodi
improv
diseas
activ
score
human
bronchial
airway
produc
sever
cell
type
includ
macrophag
eosinophil
epitheli
cell
mast
cell
inhal
produc
respons
character
increas
sputum
number
granulocyt
increas
airway
respons
furthermor
refractori
asthma
treatment
etanercept
measur
associ
improv
asthma
symptom
lung
function
airway
hyperrespons
observ
suggest
associ
bronchial
airway
inflamm
littl
known
nasal
airway
respons
man
focus
human
nasal
airway
patient
suffer
allerg
rhiniti
shown
featur
increas
tissu
express
mrna
increas
nasal
mucos
output
furthermor
preliminari
studi
shown
nasal
challeng
fail
produc
acut
effect
produc
latephas
plasma
exud
ie
extravas
lumin
entri
plasma
respons
characterist
ongo
inflamm
also
observ
respons
may
associ
increas
nasal
mucos
output
granulocyt
mediat
observ
suggest
role
upper
airway
condit
characteris
inflamm
inform
natur
respons
scarc
inform
field
warrant
sever
reason
may
use
determin
whether
antitnf
measur
evalu
upper
respiratori
tract
condit
furthermor
studi
allerg
rhiniti
may
elucid
specif
role
allerg
inflamm
may
done
allerg
asthma
featur
may
blur
chronic
inflammatori
featur
aim
present
studi
examin
characterist
inflammatori
process
evok
human
nasal
administr
nasal
challeng
carri
respons
monitor
nasal
lavag
biopsi
analysi
granulocyt
activ
plasma
exud
marker
well
tissu
number
granulocyt
base
previou
studi
focus
evalu
observ
point
hour
post
challeng
healthi
subject
patient
allerg
rhiniti
examin
season
includ
order
get
preliminari
estim
regard
whether
group
subject
differ
regard
effect
present
studi
involv
nasal
administr
singl
dose
singl
blind
shamcontrol
isoton
salin
random
crossov
design
twoweek
washout
period
nasal
lavag
carri
prior
hour
post
challeng
furthermor
nasal
mucos
biopsi
obtain
hour
postchalleng
lavag
fluid
level
myeloperoxidas
mpo
eosinophil
cation
protein
ecp
macroglobulin
measur
indic
neutrophil
activ
eosinophil
activ
plasma
exud
proinflammatori
cytokin
product
respect
number
neutrophil
eosinophil
biopsi
materi
determin
nasal
symptom
score
strateg
timepoint
thirteen
healthi
subject
femal
male
age
year
patient
season
allerg
rhiniti
femal
male
age
year
particip
studi
protocol
approv
region
ethic
committe
written
inform
consent
obtain
studi
carri
complianc
helsinki
declar
healthi
subject
inclus
criteria
neg
skin
pricktest
normal
nasal
examin
use
contracept
femal
exclus
criteria
histori
respiratori
tract
infect
within
seven
day
start
studi
allerg
nonallerg
rhiniti
nasal
diseas
structur
abnorm
rhinosinus
polyposi
use
decongest
within
seven
day
start
studi
use
treatment
except
occasion
analges
within
one
month
start
studi
patient
allerg
rhiniti
inclus
exclus
criteria
describ
except
subject
present
histori
least
two
year
season
allerg
rhiniti
posit
skinprick
test
relev
allergen
patient
posit
test
perenni
allergen
exclud
accordingli
eleven
allerg
subject
skinprick
posit
birch
timothi
grass
allergen
wherea
one
sensit
birch
alon
one
timothi
grass
alon
none
individu
posit
test
hous
dust
mite
eight
subject
posit
skinprick
test
either
cat
dog
dander
none
expos
anim
regular
basi
recombin
human
r
system
abingdon
uk
dilut
isoton
salin
concentr
solut
prepar
less
one
hour
challeng
administ
use
spraydevic
deliv
per
actuat
dose
base
experi
previou
studi
isoton
salin
use
sham
challeng
challeng
given
random
order
right
hand
side
nasal
caviti
challeng
first
visit
left
hand
side
second
visit
reason
use
nasal
caviti
avoid
influenc
first
biopsi
second
challeng
sampl
procedur
washout
period
two
week
institut
challeng
make
repeat
biopsi
procedur
toler
nasal
symptom
score
subject
prior
challeng
hour
thereaft
sneez
secret
blockag
score
fourgrad
scale
symptom
mild
symptom
moder
symptom
sever
symptom
score
ad
total
nasal
symptom
score
rang
nasal
lavag
isoton
salin
carri
use
pooldevic
volum
poolfluid
ml
kept
nasal
caviti
min
occas
lavag
perform
immedi
symptom
score
challeng
nasal
biopsi
hour
recov
fluid
centrifug
supernat
homogen
prepar
aliquot
frozen
later
analysi
result
express
weight
analyt
per
volum
without
correct
dilut
lavag
fluid
correct
dilut
may
littl
import
high
volum
lavag
employ
biopsi
obtain
immedi
second
nasal
lavag
topic
anaesthesia
appli
use
solut
lidocain
hydrochlorid
mgml
nafazolin
mgml
deliv
first
spraydevic
thereaft
cotton
swab
biopsi
taken
inferior
aspect
inferior
turbin
cm
anterior
margin
use
cuttingpunch
forcep
drill
punch
mm
diamet
haemostasi
achiev
use
diathermi
analysi
macroglobulin
measur
use
ria
sensit
ngml
rabbit
antihuman
macroglobulin
dako
copenhagen
denmark
use
antiserum
human
serum
behringwerk
marburg
germani
standard
human
macroglobulin
capellorganon
turnhout
belgium
iodin
tracer
standard
sampl
mix
antiserum
ad
goat
antirabbit
antiserum
astrazeneca
lund
sweden
bound
fraction
measur
use
gamma
counter
intraand
interassay
coeffici
variat
respect
measur
use
commerci
avail
enzymelink
immunosorb
assay
r
system
abingdon
uk
ecp
mpo
also
measur
use
commerci
avail
assay
phadia
uppsala
sweden
calbiochem
darmstadt
germani
repect
limit
detect
ecp
mpo
pgml
ngml
respect
biopsi
immers
overnight
buffer
paraformaldehyd
ph
dehydr
increas
concentr
ethanol
embed
paraffin
slice
section
rins
trisbuff
salin
section
incub
primari
monoclon
antibodi
overnight
monoclon
antibodi
phadia
dilut
detect
eosinophil
granul
protein
ecp
use
identifi
eosinophil
neutrophil
detect
monoclon
antibodi
neutrophil
granul
protein
mpo
dako
dilut
incub
primari
antibodi
specimen
rins
tb
buffer
incub
secondari
antibodi
rabbit
antimous
dako
dilut
min
room
temperatur
wash
tb
section
incub
mous
apaap
dako
dilut
nh
min
rins
develop
use
new
fuchsin
dako
substrat
endogen
alkalin
phosphatas
activ
inhibit
levamisol
dako
section
counterstain
harri
haematoxylin
coat
aqua
perm
mountant
life
sci
intern
dri
overnight
mount
kaiser
glycerol
gelatin
merck
darmstadt
germani
section
blind
number
ecpposit
eosinophil
mpoposit
neutrophil
subepitheli
cell
count
depth
epitheli
basement
membran
number
eosinophil
neutrophil
express
cellsmm
tissu
compart
differ
nasal
lavag
fluid
level
mpo
ecp
macroglobulin
well
biopsi
number
neutrophil
eosinophil
observ
follow
sham
challeng
analyz
use
wilcoxon
sign
rank
test
pvalu
less
consid
signific
data
present
mean
sem
one
patient
allerg
rhiniti
exclud
studi
airway
infect
otherwis
individu
compli
protocol
nasal
administr
produc
nasal
symptom
score
post
sham
challeng
score
post
rang
nasal
lavag
fluid
level
mpo
record
hr
post
challeng
increas
healthi
subject
p
patient
allerg
rhiniti
p
cf
sham
challeng
fig
furthermor
macroglobulin
increas
studi
group
p
p
respect
fig
indic
plasma
exud
ecp
affect
challeng
fig
increas
number
subepitheli
neutrophil
studi
materi
whole
p
fig
subgroup
analysi
reveal
chang
reflect
statist
signific
increas
healthi
group
p
allerg
rhiniti
group
p
fig
nasal
biopsi
number
eosinophil
unaffect
challeng
fig
note
nonsignific
differ
hour
post
sham
challeng
healthi
subject
patient
allerg
rhiniti
also
eosinophil
p
mann
whitney
fig
show
micrograph
nasal
mucos
neutrophil
eosinophil
hour
post
sham
challeng
respect
present
studi
involv
healthi
subject
patient
allerg
rhiniti
demonstr
intranas
produc
local
inflammatori
respons
observ
togeth
previou
find
suggest
effect
predominantli
involv
recruit
activ
neutrophil
lowgrad
exud
respons
hour
post
challeng
observ
interest
term
nasal
airway
defencephysiolog
term
whether
view
proinflammatori
factor
respiratori
condit
characteris
inflamm
dose
timepoint
monitor
present
respons
chosen
base
previou
observ
dose
may
low
shown
produc
inflammatori
effect
hour
post
challeng
present
studi
plasma
exud
produc
effect
timepoint
confirm
taken
togeth
observ
suggest
may
per
se
produc
acut
plasma
exud
human
nasal
airway
like
eg
histamin
would
induc
inflammatori
condit
characteris
latephas
plasma
exud
plasma
exud
specif
featur
inflamm
increas
level
plasma
protein
airway
mucos
surfac
liquid
character
allerg
rhiniti
upper
respiratori
tract
infect
accordingli
support
observ
increas
level
allerg
rhiniti
well
common
cold
may
proinflammatori
factor
inflammatori
condit
nasal
airway
nasal
lavag
fluid
level
mpo
increas
hour
post
administr
healthi
subject
patient
allerg
rhiniti
studi
find
agreement
previou
observ
allerg
rhiniti
although
particular
increas
mpo
reach
borderlin
statist
signific
moreov
present
studi
nasal
biopsi
number
neutrophil
studi
group
whole
significantli
increas
post
challeng
indic
neutrophilact
effect
cytokin
find
agreement
observ
thoma
et
al
report
sputum
neutrophilia
healthi
subject
well
patient
mild
asthma
follow
inhal
also
agreement
observ
vitro
identifi
factor
attract
potenti
activ
neutrophil
granulocyt
taken
togeth
availnas
lavag
fluid
level
mpo
prior
hour
post
sham
challeng
abl
inform
indic
involv
neutrophil
recruit
activ
human
airway
specif
explan
present
numer
higher
level
mpo
observ
healthi
subject
cf
patient
allerg
rhiniti
follow
challeng
howev
differ
statist
signific
p
mann
whitney
previou
studi
involv
patient
allerg
rhiniti
examin
season
observ
moder
increas
lavag
fluid
level
ecp
hour
nasal
challeng
contrast
present
studi
observ
could
confirm
specif
explan
discrep
find
variabl
eosinophil
activ
baselin
may
one
option
thoma
et
al
observ
inhal
mild
asthmat
increas
eosinophil
infiltr
wherea
case
healthi
subject
present
studi
biopsi
analysi
provid
addit
aspect
cellular
activ
show
produc
recruit
eosinophil
accordingli
overal
conclus
administ
patient
allerg
rhiniti
season
may
degre
nasal
eosinophilia
mark
season
allergen
exposur
produc
mark
proeosinophil
effect
studi
warrant
examin
effect
eosinophil
activ
tent
involv
patient
ongo
allerg
rhiniti
present
studi
power
discrimin
healthi
subject
patient
allerg
rhiniti
may
allow
preliminari
comparison
differ
induc
effect
group
nasal
lavag
fluid
level
ecp
prior
hour
post
sham
challeng
nasal
mucos
number
neutrophil
increas
healthi
subject
follow
challeng
patient
allerg
rhiniti
howev
produc
numer
increas
neutrophil
also
allerg
rhiniti
reach
statist
signific
possibl
due
somewhat
higher
baselin
furthermor
mpo
marker
neutrophil
activ
significantli
increas
studi
group
taken
togeth
mark
differ
emerg
healthi
subject
patient
allerg
rhiniti
regard
effect
howev
studi
may
warrant
order
elucid
whether
specif
role
allerg
airway
condit
studi
warrant
base
observ
patient
allerg
rhiniti
featur
increas
tissu
express
mrna
protein
moreov
basi
explor
may
recent
observ
mice
sensit
ovalbumin
subject
gene
therapi
solubl
receptor
iggfc
fusion
gene
present
decreas
symptom
attenu
aggreg
mast
cell
eosinophil
posit
cell
follow
nasal
ovalbumin
challeng
tent
human
vivo
studi
may
involv
intervent
measur
allerg
rhiniti
season
allergen
exposur
drug
includ
etanercept
emerg
possibl
treatment
option
refractori
asthma
reduct
symptom
improv
lung
function
reduct
bronchial
hyperrespons
result
intervent
similar
use
drug
allerg
rhiniti
opinion
like
part
reflect
exist
treatment
option
good
part
inherit
difficulti
current
approach
howev
human
nasal
airway
allerg
rhiniti
use
monitor
effect
studi
drug
may
particularli
valid
sinc
key
similar
inflammatori
process
upper
lower
airway
sinc
observ
made
upper
airway
condit
frequent
number
subepitheli
neutrophil
nasal
biopsi
obtain
hour
post
sham
challeng
healthi
subject
patient
allerg
rhiniti
figur
number
subepitheli
neutrophil
nasal
biopsi
obtain
hour
post
sham
challeng
healthi
subject
patient
allerg
rhiniti
p
sham
translat
bronchial
airway
diseas
sinc
nasal
airway
studi
easier
perform
context
present
find
suggest
indirectli
benefici
effect
drug
refractori
asthma
may
reflect
antineutrophil
rather
antieosinophil
effect
topic
produc
nasal
inflammatori
respons
human
potenti
mediat
increas
neutrophil
activ
micrograph
show
nasal
mucos
neutrophil
eosinophil
hour
post
sham
challeng
